EDIT Quote, Trading Chart, Editas Medicine Inc.
home / stock / edit / edit quote
$ Last:
Change Percent:
$ Open:
$ Previous Close:
$ High:
$ Low:
0 Volume:
01/01/1970 12:00:00 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-05 | 42.41 | 41.63 | 42.94 | 36.1 | 3,821,361 |
| 2021-03-04 | 42.665 | 40.36 | 43.3789 | 37.63 | 4,280,826 |
| 2021-03-03 | 45.4 | 43.13 | 45.6 | 42.0026 | 2,708,208 |
| 2021-03-02 | 46.94 | 45.69 | 48.2399 | 45.46 | 1,484,747 |
| 2021-03-01 | 44.22 | 46.89 | 47.9399 | 44.07 | 2,307,337 |
| 2021-02-26 | 45.09 | 43.86 | 46.2427 | 42.33 | 3,037,881 |
| 2021-02-25 | 49.34 | 44.76 | 50.9 | 44.3 | 3,540,228 |
| 2021-02-24 | 50.23 | 49.7 | 50.89 | 47.3326 | 2,305,544 |
| 2021-02-23 | 49.9 | 49.14 | 50.16 | 44.17 | 3,905,834 |
| 2021-02-22 | 56 | 52.42 | 56.2499 | 51.34 | 2,045,695 |
| 2021-02-19 | 56.6498 | 56.49 | 58.27 | 55.7 | 1,872,198 |
| 2021-02-18 | 54.5 | 55.36 | 56.24 | 53.83 | 2,073,336 |
| 2021-02-17 | 55.94 | 56.51 | 56.51 | 52.75 | 2,733,812 |
| 2021-02-16 | 59.25 | 56.45 | 59.43 | 55.8 | 2,079,344 |
| 2021-02-15 | 57.17 | 57.94 | 59.3 | 54.7 | 2,463,292 |
| 2021-02-12 | 57.17 | 57.94 | 59.3 | 54.7 | 2,453,892 |
| 2021-02-11 | 60.31 | 57.17 | 60.9199 | 56.28 | 3,222,622 |
| 2021-02-10 | 67.76 | 59.11 | 68.9 | 58.9 | 4,424,383 |
| 2021-02-09 | 69.81 | 66.73 | 70.06 | 64.26 | 3,041,442 |
| 2021-02-08 | 65 | 69.75 | 70.4 | 63.51 | 3,277,470 |
News, Short Squeeze, Breakout and More Instantly...
-
In this video from Motley Fool Live , recorded on Feb. 22 , Fool.com contributors Brian Orelli and Keith Speights discuss the recent downturn in Editas Medicine 's (NASDAQ: EDIT) stock price and the biotech's change in management. The valuation is an issue in the sho...
-
Image source: The Motley Fool. Editas Medicine, Inc. (NASDAQ: EDIT) Q4 2020 Earnings Call Feb 25, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript
-
Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer Appointed Meeta Chatterjee, Ph.D., to Board of Directors Initiated dosing of adult mid-dose cohort of BRILLIANCE tri...